MyFinsight
Home
Blog
About
Comprehensive loss
-$93,842,000
(55.02%↑ Y/Y)
Foreign currency
translation adjustment
$6,000
(-92.50%↓ Y/Y)
Net loss
-$91,154,000
(56.29%↑ Y/Y)
Unrealized (gain) loss on
marketable securities
-$2,694,000
(-1448.28%↓ Y/Y)
Other income, net
$27,075,000
(22.69%↑ Y/Y)
Net loss before
income taxes
-$90,194,000
(56.48%↑ Y/Y)
Provision for income taxes
$960,000
(-25.70%↓ Y/Y)
Total other income,
net
$27,075,000
(22.69%↑ Y/Y)
Collaboration Revenue
$10,000,000
Grant
$181,000
(-79.71%↓ Y/Y)
Loss from operations
-$117,269,000
(48.86%↑ Y/Y)
Total revenue
$10,181,000
(1041.37%↑ Y/Y)
Total operating
expenses
$127,450,000
(-44.64%↓ Y/Y)
Research and development
$67,152,000
(-3.92%↓ Y/Y)
Collaboration expense, net
$40,272,000
(-10.81%↓ Y/Y)
General and
administrative
$17,553,000
(-7.21%↓ Y/Y)
Acquired in-process
research and development
$2,473,000
(-97.43%↓ Y/Y)
Back
Back
Income Statement
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)
source: myfinsight.com